Trends in endometrial cancer incidence rates in the United States, 1999-2006

Journal of Women's Health

Volumn 20, Issue 8, 2011, Pages 1157-1163

  Duong, Linh M ^a   Wilson, Reda J ^a   Ajani, Umed A ^a   Singh, Simple D ^a   Eheman, Christie R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER REGISTRY; COMPARATIVE STUDY; ENDOMETRIUM CANCER; FEMALE; HISTOLOGY; HUMAN; PRIORITY JOURNAL; UNITED STATES; UTERUS CANCER;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ENDOMETRIAL NEOPLASMS; ETHNIC GROUPS; FEMALE; HISTOLOGICAL TECHNIQUES; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; INFANT; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OBESITY; POSTMENOPAUSE; RISK FACTORS; SARCOMA, ENDOMETRIAL STROMAL; UNITED STATES; YOUNG ADULT;

EID: 80051715595     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2529     Document Type: Article

References (48)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2006 Incidence and mortality web-based report. Atlanta: U.S.Department ofHealth and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2010. Available at www.cdc.gov/uscs
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. Cancer J Clin 2009;59:225-249.
3. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2005 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at www.cdc.gov/uscs
4. Katz VL, Lentz GM, Lobo RA, eds. Comprehensive gynecology, 5th ed. Philadelphia, PA: Mosby Elsevier, 2007.
5. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008;108:221-229. (Pubitemid 351179637)
6. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwanese J Obstet Gynecol 2007;46:26-32.
7. Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: Endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2006;20:363-377. (Pubitemid 43380605)
8. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology (Phil) 2007;39:46-54.
9. Bansal N, Yendluri V, Wenham R. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009;16:8-13.
10. Mylonas I. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep 2010;24:385-393.
11. Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California Teachers Study cohort. Cancer Causes Control 2010;21:1407-1416.
12. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 2010;21:1851-1856.
13. Boruta DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;115:142-153.
14. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17. (Pubitemid 13194678)
15. Hecht J, Mutter G. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-4791. (Pubitemid 46630943)
16. Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res 2007;27:1213-1217. (Pubitemid 46587043)
17. Tavassoli FA, Devilee P, eds. World Health Organization classification of tumours: Pathology and genetics of tumours of the breast and female genital organs. Lyon, France: IARC Press, 2003.
18. Sabatino SA, Stewart SL, Wilson RJ. Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001-2003. J Womens Health 2009;18:285-294.
19. Edwards B, Ward E, Kohler B, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-573.
20. Ueda S, Kapp D, Cheung M, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218 e211-216.
21. Plaxe SC, Saltzstein SL. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol 1997;65: 8-12. (Pubitemid 27171545)
22. Madison T, SchottenfeldD, Baker V. Cancer of the corpus uteri in white and black women in Michigan, 1985-1994: An analysis of trends in incidence and mortality and their relation to histologic subtype and stage. Cancer 1998;83:1546-1554. (Pubitemid 28465472)
23. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endoc Rel Cancer 2000;7:227-242. (Pubitemid 32175106)
24. McCullough Ml, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008; 17:73-79. (Pubitemid 351196275)
25. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008;34:776-783.
26. Hersh A, Stefanick M, Stafford R. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004;291:47-53. (Pubitemid 38040534)
27. Richardson LC, Thomas C, Bowman BA. Obesity and endometrial cancer: Challenges for public health action. Womens Health 2009;5:595-597.
28. Karageorgi S, Hankinson SE, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer 2010;126:208-216.
29. Mylonas I, Jeschke U, Shabani N, et al. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 2005;25:1679-1686. (Pubitemid 40896785)
30. Shabani N, Mylonas I, Jeschke U, et al. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res 2007;27:2027-2033. (Pubitemid 46954720)
31. Thomas CC, Wingo PA, Dolan MS, Lee NC, Richardson LC. Endometrial cancer risk among younger, overweight women. Obstet Gynecol 2009;114:22-27.
32. Chang SC, Lacey JV Jr, Brinton LA, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP Diet and Health Study. Cancer Epidemiol Biomarkers Prev 2007;16: 723-730. (Pubitemid 46650574)
33. Comerci J, Fields A, Runowicz C, Goldberg G. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. Gynecol Oncol 1997;64: 425-430. (Pubitemid 27120430)
34. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304-313.
35. Lacey J, Brinton L, Lubin J, Sherman M, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1724-1731. (Pubitemid 40995086)
36. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116. (Pubitemid 27337924)
37. Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Cancer Surveillance Branch, National Program of Cancer Registries: United States Cancer Statistics (USCS) TechnicalNotes. Available atwww.cdc.gov/ cancer/npcr/uscs/2002/pdf/technical-notes.pdf Accessed June 30, 2010.
38. Centers forDiseaseControl and Prevention, Division of Cancer Prevention and Control, Cancer Surveillance Branch, National Program of Cancer Registries: United States Cancer Statistics (USCS) Publication Standards. Available at www.cdc.gov/ cancer/npcr/uscs/2004/qa.htm#7 Accessed June 30, 2010.
39. Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Cancer Surveillance Branch, 2008/2009 National Program of Cancer Registries: Facts sheet. Available at www.cdc.gov/cancer/npcr/npcrpdfs/0809- npcr-fs.pdf Accessed June 30, 2010.
40. World Health Organization. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization, 1990.
41. World Health Organization. International classification of diseases for oncology, 3rd ed. Geneva: World Health Organization, 2000.
42. Surveillance Research Program, National Cancer Institute SEER. Stat software version 6.6.2. Available www.seer .cancer.gov/seerstat
43. Young J, Roffers S, Ries L, Fritz A, Hurlbut A. SEER summary staging manual 2000. Bethesda, MD: National Cancer Institute, 2000.
44. Hamilton C, Cheung M, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642-646. (Pubitemid 43361894)
45. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
46. Ito K. Hormone replacement therapy and cancers: The biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J Exp Med 2007;212:1-12. (Pubitemid 46711719)
47. Stefanick ML. Estrogens and progestins: Background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118(Suppl 12B):64-73.
48. Cogliano V, Grosse Y, Baan R, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552-553. (Pubitemid 41051931)